Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

December 31, 2009

Study Completion Date

July 31, 2010

Conditions
Alopecia TotalisAlopecia UniversalisOphiasic Alopecia
Interventions
DRUG

methylprednisolone sodium succinate

Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

DRUG

methylprednisolone sodium succinate

Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

DRUG

methylprednisolone sodium succinate

Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.

Trial Locations (1)

11472

King Khalid University Hospital, Riyadh

All Listed Sponsors
collaborator

Saudi Society of Dermatology and Dermatologic surgery

UNKNOWN

lead

King Saud University

OTHER

NCT01167946 - Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata | Biotech Hunter | Biotech Hunter